Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from the blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics.

The Acute Renal Failure drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Renal Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure and features dormant and discontinued projects.

Key Targets in the Acute Renal Failure Pipeline Products Market

The key targets in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase, Alkaline Phosphatase, Free Radical, Peroxisome Proliferator Activated Receptor Delta, Renalase, Alpha 1 Adrenergic Receptor, Alpha 2B Adrenergic Receptor, Atrial Natriuretic Peptide Receptor 1, C-X-C Chemokine Receptor Type 4, and others.

Acute Renal Failure Pipeline Products Analysis Market by Targets

Acute Renal Failure Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Acute Renal Failure Pipeline Products Market

The key mechanisms of action in the Acute Renal Failure pipeline products market are Angiopoietin 1 Receptor Agonist, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase Inhibitor, Alkaline Phosphatase Replacement, Free Radical Scavenger, Peroxisome Proliferator Activated Receptor Delta Agonist, Renalase Activator, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2B Adrenergic Receptor Agonist, Atrial Natriuretic Peptide Receptor 1 Agonist, C-X-C Chemokine Receptor Type 4 Agonist, and others.

Acute Renal Failure Pipeline Products Market Analysis by Mechanism of Actions

Acute Renal Failure Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Acute Renal Failure Pipeline Products Market

The key routes of administration in the Acute Renal Failure pipeline products market are intravenous, oral, subcutaneous, intramuscular, intrathecal, intravenous bolus, parenteral, topical, inhalational, intraarticular, and others.

Acute Renal Failure Pipeline Products Market Analysis by Routes of Administration

Acute Renal Failure Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Acute Renal Failure Pipeline Products Market

The key molecule types in the Acute Renal Failure pipeline products market are small molecule, recombinant protein, cell therapy, recombinant enzyme, synthetic peptide, fusion protein, antisense RNAi oligonucleotide, biologic, recombinant peptide, monoclonal antibody, and others.

Acute Renal Failure Pipeline Products Market Analysis by Molecule Type

Acute Renal Failure Pipeline Products Market Analysis by Molecule TypeFor more molecule type insights, download a free report sample

Major Companies in the Acute Renal Failure Pipeline Products Market

Some of the major companies in the Acute Renal Failure pipeline products market are Angion Biomedica Corp, Arch Biopartners Inc, Goldilocks Therapeutics Inc, Johnson & Johnson, Mitobridge Inc, Q BioMed Inc, TES Pharma SRL, Alloksys Life Sciences BV, Am-Pharma BV, and Amniotics AB.

Acute Renal Failure Pipeline Products Market Analysis by Companies

Acute Renal Failure Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Angiopoietin 1 Receptor, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase, Alkaline Phosphatase, Free Radical, Peroxisome Proliferator Activated Receptor Delta, Renalase, Alpha 1 Adrenergic Receptor, Alpha 2B Adrenergic Receptor, Atrial Natriuretic Peptide Receptor 1, C-X-C Chemokine Receptor Type 4, and Others
Key mechanism of action Angiopoietin 1 Receptor Agonist, 2 Amino 3 Carboxymuconate 6 Semialdehyde Decarboxylase Inhibitor, Alkaline Phosphatase Replacement, Free Radical Scavenger, Peroxisome Proliferator Activated Receptor Delta Agonist, Renalase Activator, Alpha 1 Adrenergic Receptor Antagonist, Alpha 2B Adrenergic Receptor Agonist, Atrial Natriuretic Peptide Receptor 1 Agonist, C-X-C Chemokine Receptor Type 4 Agonist, and Others
Key routes of administration Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal, Intravenous Bolus, Parenteral, Topical, Inhalational, Intraarticular, and Others
Key molecule type Small Molecule, Recombinant Protein, Cell Therapy, Recombinant Enzyme, Synthetic Peptide, Fusion Protein, Antisense RNAi Oligonucleotide, Biologic, Recombinant Peptide, Monoclonal Antibody, and Others
Major companies Angion Biomedica Corp, Arch Biopartners Inc, Goldilocks Therapeutics Inc, Johnson & Johnson, Mitobridge Inc, Q BioMed Inc, TES Pharma SRL, Alloksys Life Sciences BV, Am-Pharma BV, and Amniotics AB

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from the company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Alloksys Life Sciences BV
Am-Pharma BV
Amniotics AB
Anagenics Ltd
Angion Biomedica Corp
Angiotensin Therapeutics Inc
Arch Biopartners Inc
Ashvattha Therapeutics LLC
Axolo Pharma Inc
Balmes Transplantation SAS
Bessor Pharma LLC
CFM Pharma Holding BV
Chaperone Pharma BV
Claritas Pharmaceuticals Inc
Curigin Co Ltd
Cypralis Ltd
DURECT Corp
Evotec SE
Exponential Biotherapies Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
GeneScience Pharmaceuticals Co Ltd
Goldilocks Therapeutics Inc
Guard Therapeutics International AB
Haisco Pharmaceutical Group Co Ltd
HemaFlo Therapeutics Inc
Hybridize Pharma BV
iCELL Biotechnology Co Ltd
ILIAS Biologics Inc
Johnson & Johnson
Kantum Pharma Inc
Klotho Therapeutics Inc
Kringle Pharma Inc
Liminal BioSciences Inc
LTT Bio-Pharma Co Ltd
Meridigen Biotech Co Ltd
Metro International Biotech LLC
Mission Therapeutics Ltd
Mitobridge Inc
Mitotech SA
Mitotherapeutix LLC
NeoProgen Inc
Nephraegis Therapeutics
Orgenesis Inc
Paranta Biosciences Ltd
Pharmazz Inc
Pharmicell Co Ltd
Pharming Group NV
Praetego Inc
Q BioMed Inc
Radikal Therapeutics Inc
Rediscovery Life Sciences
Renibus Therapeutics Inc
Rui Nuo Medical Technology (Shanghai) Co Ltd
Sentien Biotechnologies Inc
Sidereal Therapeutics Inc
Silver Creek Pharmaceuticals Inc
Slate Bio Inc
STATegics Inc
Sulfateq BV
TES Pharma SRL
TheraSource LLC
Theratome Bio Inc
Unicycive Therapeutics Inc
Unicyte AG
Valo Health LLC
Vasculonics LLC
Vasomune Inc
vasopharm GmbH
Vivoryon Therapeutics NV
Xigen SA
XORTX Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Renal Failure (ARF) (Acute Kidney Injury) – Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Renal Failure (ARF) (Acute Kidney Injury) – Companies Involved in Therapeutics Development

Acute Renal Failure (ARF) (Acute Kidney Injury) – Drug Profiles

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) – Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: AM-Pharma announces two presentations at the 27th International Conference on Advances in Critical Care Nephrology

Feb 15, 2022: Haisco’s announcement on obtaining the “Notice of Acceptance” for clinical trial application of innovative drug HSK36212 capsules

Feb 03, 2022: Arch Scientists publish data on the mechanism of action and efficacy of lead drug candidate LSALT peptide in the prevention of acute kidney injury

Dec 09, 2021: Angion and Vifor Pharma report topline results from phase 2 GUARD trial of ANG-3777 in cardiac surgery-associated acute kidney injury

Oct 14, 2021: XORTX announces results from Mount Sinai’s COVID-19 clinical study

Aug 05, 2021: Arch Biopartners provides update on phase II trial for LSALT peptide

Jul 01, 2021: AM-Pharma enrolls first patient in Japan for ongoing phase III SA-AKI pivotal REVIVAL trial

Jun 28, 2021: ILIAS Biologics demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury

Jun 17, 2021: KBI Biopharma enters commercial manufacturing agreement with AM-Pharma to prepare for the commercial launch of lead program in acute kidney disease

Jun 10, 2021: Arch Biopartners files new patent application for novel antibody candidates targeting DPEP-1 mediated organ inflammation

May 03, 2021: Lyfaquin, a resuscitative agent marketed in India, restores renal blood flow and protects tissue damage after hemorrhagic shock-induced acute kidney injury (AKI)

Apr 29, 2021: Angion and Vifor Pharma announce completion of enrollment in phase 2 study of ANG-3777 for cardiac-surgery associated acute kidney injury

Apr 22, 2021: Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST for the prevention of acute kidney injury after myocardial infarction

Mar 30, 2021: Turkish Ministry of Health approves increase in patient recruitment into the phase II trial for LSALT peptide

Mar 17, 2021: Arch Biopartners secures approval to amend LSALT Peptide trial protocols

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Alloksys Life Sciences BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Am-Pharma BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Amniotics AB, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Anagenics Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Angion Biomedica Corp, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Angiotensin Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Arch Biopartners Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Ashvattha Therapeutics LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Axolo Pharma Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Balmes Transplantation SAS, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Bessor Pharma LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by CFM Pharma Holding BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Chaperone Pharma BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Claritas Pharmaceuticals Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Curigin Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Cypralis Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by DURECT Corp, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Evotec SE, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Exponential Biotherapies Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Faron Pharmaceuticals Oy, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Goldilocks Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Guard Therapeutics International AB, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by HemaFlo Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Hybridize Pharma BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by iCELL Biotechnology Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by ILIAS Biologics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Johnson & Johnson, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Kantum Pharma Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Klotho Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Kringle Pharma Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Liminal BioSciences Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by LTT Bio-Pharma Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Meridigen Biotech Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Metro International Biotech LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mission Therapeutics Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitobridge Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitotech SA, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitotherapeutix LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by NeoProgen Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Nephraegis Therapeutics, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Orgenesis Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Paranta Biosciences Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Pharmazz Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Pharmicell Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Pharming Group NV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Praetego Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Q BioMed Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Radikal Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Rediscovery Life Sciences, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Renibus Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Rui Nuo Medical Technology (Shanghai) Co Ltd, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Sentien Biotechnologies Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Sidereal Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Silver Creek Pharmaceuticals Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Slate Bio Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by STATegics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Sulfateq BV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by TES Pharma SRL, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by TheraSource LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Theratome Bio Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Unicycive Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Unicyte AG, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Valo Health LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Vasculonics LLC, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Vasomune Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by vasopharm GmbH, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Vivoryon Therapeutics NV, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Xigen SA, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by XORTX Therapeutics Inc, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, 2022

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, 2022 (Contd..1)

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, 2022 (Contd..2)

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.